@article{TLCR24650,
author = {Maria Gonzalez-Cao and Santiago Viteri and Niki Karachaliou and Andres Aguilar and Juan Jose García-Mosquera and Rafael Rosell},
title = {Tumor mutational burden as predictive factor of response to immunotherapy},
journal = {Translational Lung Cancer Research},
volume = {7},
number = {Suppl 4},
year = {2018},
keywords = {},
abstract = {In May 2018, Hellmann et al. published in Cancer Cell journal a retrospective study analyzing the predictive value of tumor mutational burden (TMB) in 75 non-small cell lung cancer (NSCLC) patients treated with the combination of the anti PD-1 inhibitor nivolumab and the anti CTLA-4 antibody ipilimumab in the Check-Mate 012 study.},
issn = {2226-4477}, url = {https://tlcr.amegroups.org/article/view/24650}
}